Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045558406> ?p ?o ?g. }
- W2045558406 endingPage "224" @default.
- W2045558406 startingPage "217" @default.
- W2045558406 abstract "Background: Ifosfamide and doxorubicin combination is an active regimen for patients with advanced soft tissue sarcomas (STS) but is burdened by high toxicity. A phase II trial was designed to assess the activity of continuous infusion ifosfamide and doxorubicin combination. Patients and Methods: Thirty-four chemotherapy-naive patients with advanced STS were treated with ifosfamide (13 g/m2/12 days as continuous infusion) and doxorubicin (75 mg/m2 on day 8) every 28 days with granulocyte colony-stimulating factor. Results: The major toxicity was hematological: grade 3/4 neutropenia, anemia and thrombocytopenia occurred in 63, 30 and 12% of patients, respectively. The disease control rate was 68% and the median time to progression was 7.1 months. Among leiomyosarcomas, 2 partial responses and 4 stable diseases were observed. Conclusions: Our study confirms that the ifosfamide and doxorubicin combination has a very low non-hematological toxicity profile. This regimen attained a high disease control rate with moderate activity. Further investigation into leiomyosarcoma is warranted." @default.
- W2045558406 created "2016-06-24" @default.
- W2045558406 creator A5009015207 @default.
- W2045558406 creator A5014792832 @default.
- W2045558406 creator A5023762335 @default.
- W2045558406 creator A5034667041 @default.
- W2045558406 creator A5038247051 @default.
- W2045558406 creator A5038305710 @default.
- W2045558406 creator A5038784620 @default.
- W2045558406 creator A5049793416 @default.
- W2045558406 creator A5052353123 @default.
- W2045558406 creator A5062234802 @default.
- W2045558406 creator A5064222874 @default.
- W2045558406 creator A5064646828 @default.
- W2045558406 creator A5065156213 @default.
- W2045558406 creator A5079789461 @default.
- W2045558406 creator A5085512648 @default.
- W2045558406 date "2011-01-01" @default.
- W2045558406 modified "2023-10-18" @default.
- W2045558406 title "Optimizing Clinical Care in Patients with Advanced Soft Tissue Sarcoma: A Phase II Study of a New Schedule of High-Dose Continuous Infusion Ifosfamide and Doxorubicin Combination" @default.
- W2045558406 cites W1748728040 @default.
- W2045558406 cites W1828438395 @default.
- W2045558406 cites W1876135160 @default.
- W2045558406 cites W1943427806 @default.
- W2045558406 cites W1964751712 @default.
- W2045558406 cites W1971135375 @default.
- W2045558406 cites W1971706933 @default.
- W2045558406 cites W1978253188 @default.
- W2045558406 cites W1980428198 @default.
- W2045558406 cites W1984254136 @default.
- W2045558406 cites W1999662775 @default.
- W2045558406 cites W1999680634 @default.
- W2045558406 cites W2003743385 @default.
- W2045558406 cites W2014590906 @default.
- W2045558406 cites W2017670066 @default.
- W2045558406 cites W2033600624 @default.
- W2045558406 cites W2051027520 @default.
- W2045558406 cites W2055717999 @default.
- W2045558406 cites W2071993782 @default.
- W2045558406 cites W2084869046 @default.
- W2045558406 cites W2111844892 @default.
- W2045558406 cites W2120113475 @default.
- W2045558406 cites W2134281922 @default.
- W2045558406 cites W2139248078 @default.
- W2045558406 cites W2145828205 @default.
- W2045558406 cites W2149072358 @default.
- W2045558406 cites W2149843972 @default.
- W2045558406 cites W2153365867 @default.
- W2045558406 cites W2161378536 @default.
- W2045558406 cites W2224867602 @default.
- W2045558406 cites W2230867484 @default.
- W2045558406 cites W2266212450 @default.
- W2045558406 cites W2417748545 @default.
- W2045558406 cites W3041047318 @default.
- W2045558406 cites W4301170697 @default.
- W2045558406 doi "https://doi.org/10.1159/000326466" @default.
- W2045558406 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21597285" @default.
- W2045558406 hasPublicationYear "2011" @default.
- W2045558406 type Work @default.
- W2045558406 sameAs 2045558406 @default.
- W2045558406 citedByCount "4" @default.
- W2045558406 countsByYear W20455584062012 @default.
- W2045558406 countsByYear W20455584062013 @default.
- W2045558406 countsByYear W20455584062014 @default.
- W2045558406 countsByYear W20455584062015 @default.
- W2045558406 crossrefType "journal-article" @default.
- W2045558406 hasAuthorship W2045558406A5009015207 @default.
- W2045558406 hasAuthorship W2045558406A5014792832 @default.
- W2045558406 hasAuthorship W2045558406A5023762335 @default.
- W2045558406 hasAuthorship W2045558406A5034667041 @default.
- W2045558406 hasAuthorship W2045558406A5038247051 @default.
- W2045558406 hasAuthorship W2045558406A5038305710 @default.
- W2045558406 hasAuthorship W2045558406A5038784620 @default.
- W2045558406 hasAuthorship W2045558406A5049793416 @default.
- W2045558406 hasAuthorship W2045558406A5052353123 @default.
- W2045558406 hasAuthorship W2045558406A5062234802 @default.
- W2045558406 hasAuthorship W2045558406A5064222874 @default.
- W2045558406 hasAuthorship W2045558406A5064646828 @default.
- W2045558406 hasAuthorship W2045558406A5065156213 @default.
- W2045558406 hasAuthorship W2045558406A5079789461 @default.
- W2045558406 hasAuthorship W2045558406A5085512648 @default.
- W2045558406 hasConcept C126322002 @default.
- W2045558406 hasConcept C126894567 @default.
- W2045558406 hasConcept C136948725 @default.
- W2045558406 hasConcept C141071460 @default.
- W2045558406 hasConcept C142724271 @default.
- W2045558406 hasConcept C143998085 @default.
- W2045558406 hasConcept C2776694085 @default.
- W2045558406 hasConcept C2777063308 @default.
- W2045558406 hasConcept C2777506904 @default.
- W2045558406 hasConcept C2777532014 @default.
- W2045558406 hasConcept C2778119113 @default.
- W2045558406 hasConcept C2778256501 @default.
- W2045558406 hasConcept C2778629024 @default.
- W2045558406 hasConcept C2781303535 @default.
- W2045558406 hasConcept C2781413609 @default.
- W2045558406 hasConcept C29730261 @default.
- W2045558406 hasConcept C31760486 @default.